Real-time Artificial Intelligence-based Speech Enhancement Methods for Hearing Aid Improvement

Last updated: March 14, 2024
Sponsor: Institut Pasteur
Overall Status: Active - Recruiting

Phase

N/A

Condition

Deafness

Treatment

audiological measurements

Objective and subjective audiological measurements

Evaluation of the denoising methods REFINED

Clinical Study ID

NCT05985473
2022-016
2023-A00140-45
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Individuals with Auditory Neuropathy Spectrum Disorders (ANSD) represent 1-10% of adults with hearing loss. These individuals have little or no benefit from current hearing aids because ANSD is a continuum of hearing impairments due to synaptic or neural dysfunction in the peripheral and central parts of the auditory pathways, which impairs temporal information processing without necessarily affecting auditory sensitivity. There is a need to find ad-hoc denoising methods, based on the expert knowledge of audiologists, to improve the noise comprehension performance of these patients. Implemented denoising methods, based on artificial intelligence, will also greatly benefit more standard hearing loss cases.

Eligibility Criteria

Inclusion

Inclusion Criteria: For all participants:

  • Age greater than or equal to 18 years,

  • French mother tongue,

  • Have an average tonal hearing loss (calculated according to the BIAP method) < 30 dBHL, on headphones, for each ear,

  • Be professionally active, not be pre-retired and not be unemployed

  • Be affiliated with a social security plan, For participants with TSNA:

  • Have degraded comprehension in noise (threshold of Intelligibility in Noise > 3 dBcompared to the norm). For controls:

  • Have normal comprehension in noise (Intelligibility in Noise threshold ≤ 3 dB from thenorm).

Exclusion

Exclusion Criteria: For all participants:

  • Have a conductive or mixed hearing loss, which is when the hearing loss affects boththe outer and/or middle ear and the inner ear.
  • Have an asymmetric hearing loss, i.e. a difference in average hearing loss between theleft and right ear greater than 30 dB,
  • Have sequelae of ear infections and/or a history of ENT disease that permanentlyaffects hearing (vestibular schwannoma, Meniere's disease, sudden or fluctuatingdeafness, congenital hypoacusis)
  • Being under guardianship,
  • Being deprived of liberty by judicial or administrative decision, or being subject tolegal protection.

Study Design

Total Participants: 40
Treatment Group(s): 3
Primary Treatment: audiological measurements
Phase:
Study Start date:
March 06, 2024
Estimated Completion Date:
September 15, 2026

Study Description

Longitudinal study consisting of multiple visits with multiple examinations over a total duration of approximately 3 years per ANSD participant and 1 year per normal hearing participant.

  • normal hearing participant : year 1 : Inclusion visit, Phenotyping visit (Audiological tests), Follow-up Visit 1 (Noise Comprehension Tests)

  • ANSD participant : year 1 : Inclusion visit, Phenotyping visit (Audiological tests), Follow-up Visit 1 (Noise Comprehension Tests) year 2 : Follow-up Visit 2 (Noise Comprehension Tests) year 3 : Follow-up Visit 3 (Noise Comprehension Tests)

Connect with a study center

  • CEntre de Recherche et d'Innovation en Audiologie Humaine

    Paris,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.